{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T21:03:48Z","timestamp":1784840628246,"version":"3.55.0"},"reference-count":146,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jacasi.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:30:24Z","timestamp":1784838624000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac-Adipose Axis in Heart Failure With Preserved Ejection Fraction"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-5616","authenticated-orcid":false,"given":"Rubin","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7988-3090","authenticated-orcid":false,"given":"Tao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3308-0265","authenticated-orcid":false,"given":"Chunxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib1","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.2115","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.jacasi.2026.06.006_bib2","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.jacc.2023.01.049","article-title":"Heart failure with preserved ejection fraction: JACC scientific statement","volume":"81","author":"Borlaug","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib3","article-title":"Phenotypes and clinical outcome of heart failure with preserved ejection fraction patients in China: findings from the Chinese cardiovascular Association database-heart failure center registry","volume":"7","author":"Yuan","year":"2026","journal-title":"MedComm (2020)"},{"issue":"20","key":"10.1016\/j.jacasi.2026.06.006_bib4","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.jacc.2025.08.036","article-title":"Central adiposity or hypertension: which drives heart failure with a preserved ejection fraction?","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib5","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/obr.12551","article-title":"Obesity: a chronic relapsing progressive disease process. A position statement of the world obesity Federation","volume":"18","author":"Bray","year":"2017","journal-title":"Obes Rev"},{"issue":"10294","key":"10.1016\/j.jacasi.2026.06.006_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(21)00798-4","article-title":"Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18","volume":"398","author":"Wang","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S2213-8587(21)00045-0","article-title":"Epidemiology and determinants of obesity in China","volume":"9","author":"Pan","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.jacasi.2026.06.006_bib8","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1111\/dom.15238","article-title":"Prevalence of obesity and associated complications in China: a cross-sectional, real-world study in 15.8 million adults","volume":"25","author":"Chen","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","article-title":"Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction","volume":"136","author":"Obokata","year":"2017","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.jacasi.2026.06.006_bib10","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1093\/eurheartj\/ehaf057","article-title":"Near-universal prevalence of central adiposity in heart failure with preserved ejection fraction: the PARAGON-HF trial","volume":"46","author":"Peikert","year":"2025","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib11","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41467-025-56885-9","article-title":"FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice","volume":"16","author":"Zhang","year":"2025","journal-title":"Nat Commun"},{"issue":"23","key":"10.1016\/j.jacasi.2026.06.006_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027164","article-title":"Diabetes and excess aldosterone promote heart failure with preserved ejection fraction","volume":"11","author":"Hegyi","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib13","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41569-020-00480-6","article-title":"Cellular and molecular pathobiology of heart failure with preserved ejection fraction","volume":"18","author":"Mishra","year":"2021","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12944-024-02266-y","article-title":"Linking abnormal fat distribution with HFpEF and diastolic dysfunction: a systematic review, meta-analysis, and meta-regression of observational studies","volume":"23","author":"Fu","year":"2024","journal-title":"Lipids Health Dis"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2337\/db15-0399","article-title":"ACE2 deficiency worsens epicardial adipose tissue inflammation and cardiac dysfunction in response to diet-induced obesity","volume":"65","author":"Patel","year":"2016","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib16","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jchf.2018.05.018","article-title":"The Association of obesity and cardiometabolic traits with incident HFpEF and HFrEF","volume":"6","author":"Savji","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"10456","key":"10.1016\/j.jacasi.2026.06.006_bib17","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(24)01643-X","article-title":"Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials","volume":"404","author":"Kosiborod","year":"2024","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.jacasi.2026.06.006_bib18","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.jacc.2025.06.055","article-title":"The adipokine hypothesis of heart failure with a preserved ejection fraction: a novel framework to explain pathogenesis and guide treatment","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.06.006_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.redox.2018.07.007","article-title":"Melatonin improves cardiac function in a mouse model of heart failure with preserved ejection fraction","volume":"18","author":"Liu","year":"2018","journal-title":"Redox Biol"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11154-023-09850-0","article-title":"An update on the secretory functions of brown, white, and beige adipose tissue: towards therapeutic applications","volume":"25","author":"Ghesmati","year":"2024","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.jacasi.2026.06.006_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15253","article-title":"Impact of fat mass and distribution on lipid turnover in human adipose tissue","volume":"8","author":"Spalding","year":"2017","journal-title":"Nat Commun"},{"issue":"15","key":"10.1016\/j.jacasi.2026.06.006_bib22","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1056\/NEJMoa0808949","article-title":"Functional brown adipose tissue in healthy adults","volume":"360","author":"Virtanen","year":"2009","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacasi.2026.06.006_bib23","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa0810780","article-title":"Identification and importance of brown adipose tissue in adult humans","volume":"360","author":"Cypess","year":"2009","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacasi.2026.06.006_bib24","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrm.2016.96","article-title":"Control of brown and beige fat development","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.jacasi.2026.06.006_bib25","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bcp.2018.07.022","article-title":"New approaches targeting brown adipose tissue transplantation as a therapy in obesity","volume":"155","author":"Soler-V\u00e1zquez","year":"2018","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nrendo.2013.204","article-title":"Adipose tissue browning and metabolic health","volume":"10","author":"Bartelt","year":"2014","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.tem.2018.01.001","article-title":"The common and distinct features of brown and beige adipocytes","volume":"29","author":"Ikeda","year":"2018","journal-title":"Trends Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib28","doi-asserted-by":"crossref","first-page":"R159","DOI":"10.1530\/EJE-13-0945","article-title":"Brown and pink adipocytes: the extraordinary plasticity of the adipose organ","volume":"170","author":"Giordano","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib29","article-title":"Epicardial adipose tissue, metabolic disorders, and cardiovascular diseases: recent advances classified by research methodologies","volume":"4","author":"Song","year":"2023","journal-title":"MedComm (2020)"},{"issue":"9","key":"10.1016\/j.jacasi.2026.06.006_bib30","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib31","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/cvr\/cvaf056","article-title":"The role of epicardial adipose tissue remodelling in heart failure with preserved ejection fraction","volume":"121","author":"Janssen-Telders","year":"2025","journal-title":"Cardiovasc Res"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib32","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","article-title":"Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies","volume":"30","author":"Malavazos","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib33","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13912","article-title":"Role of epicardial adipose tissue in heart failure with preserved ejection fraction: an emerging molecular mechanism and therapeutic potential","volume":"26","author":"Qi","year":"2025","journal-title":"Obes Rev"},{"issue":"9","key":"10.1016\/j.jacasi.2026.06.006_bib34","doi-asserted-by":"crossref","first-page":"E1448","DOI":"10.1210\/jc.2013-1265","article-title":"Adult epicardial fat exhibits beige features","volume":"98","author":"Sacks","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib35","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/ejhf.2741","article-title":"Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives","volume":"24","author":"van Woerden","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.jacasi.2026.06.006_bib36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.3390\/biom14111465","article-title":"Cardio-Lipotoxicity of epicardial adipose tissue","volume":"14","author":"Bodenstab","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.jacasi.2026.06.006_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1146\/annurev-physiol-042222-021346","article-title":"Adipose tissue in cardiovascular disease: from basic science to clinical translation","volume":"86","author":"Polkinghorne","year":"2024","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-024-02342-8","article-title":"Excessive accumulation of epicardial adipose tissue promotes microvascular obstruction formation after myocardial ischemia\/reperfusion through modulating macrophages polarization","volume":"23","author":"Zhao","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib39","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J Clin Invest"},{"issue":"20","key":"10.1016\/j.jacasi.2026.06.006_bib40","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1016\/j.jacc.2018.03.509","article-title":"Epicardial adipose tissue may mediate deleterious effects of obesity and inflammation on the myocardium","volume":"71","author":"Packer","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib41","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1161\/CIRCRESAHA.115.302922","article-title":"Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies","volume":"115","author":"Sharma","year":"2014","journal-title":"Circ Res"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ejhf.2423","volume":"24","author":"De Biase","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"17","key":"10.1016\/j.jacasi.2026.06.006_bib43","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2024.07.016","article-title":"Heart failure and obesity: unraveling molecular mechanisms of excess adipose tissue","volume":"84","author":"Dronkers","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacasi.2026.06.006_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/nutd.2016.14","article-title":"Attenuation of cold stress-induced exacerbation of cardiac and adipose tissue pathology and metabolic disorders in a rat model of metabolic syndrome by the glucocorticoid receptor antagonist RU486","volume":"6","author":"Nagasawa","year":"2016","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.jacasi.2026.06.006_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2024.116090","article-title":"Advances in heart failure monitoring: biosensors targeting molecular markers in peripheral bio-fluids","volume":"255","author":"Dong","year":"2024","journal-title":"Biosens Bioelectron"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s12933-024-02366-0","article-title":"Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis","volume":"23","author":"Shi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"10.1016\/j.jacasi.2026.06.006_bib47","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jacc.2025.04.059","article-title":"Impact of body mass index, central adiposity, and weight loss on the benefits of tirzepatide in HFpEF: the SUMMIT trial","volume":"86","author":"Borlaug","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.jacasi.2026.06.006_bib48","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.tips.2025.02.005","article-title":"Visceral obesity and HFpEF: targets and therapeutic opportunities","volume":"46","author":"Li","year":"2025","journal-title":"Trends Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib49","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ehf2.14739","article-title":"Epicardial adipose tissue and pericardial constraint in heart failure with preserved ejection fraction","volume":"11","author":"Crum","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"11","key":"10.1016\/j.jacasi.2026.06.006_bib50","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1002\/ejhf.2337","article-title":"Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure","volume":"23","author":"Pugliese","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib51","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jchf.2020.04.016","article-title":"Hemodynamic and functional impact of epicardial adipose tissue in heart failure with preserved ejection fraction","volume":"8","author":"Koepp","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"13","key":"10.1016\/j.jacasi.2026.06.006_bib52","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.7150\/ijbs.82844","article-title":"Single-cell transcriptomics reveals zinc and copper ions homeostasis in epicardial adipose tissue of heart failure","volume":"19","author":"Zou","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s00395-016-0591-0","article-title":"Secretory products from epicardial adipose tissue from patients with type 2 diabetes impair mitochondrial \u03b2-oxidation in cardiomyocytes via activation of the cardiac renin-angiotensin system and induction of miR-208a","volume":"112","author":"Blumensatt","year":"2017","journal-title":"Basic Res Cardiol"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib54","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/cvr\/cvt173","article-title":"Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143","volume":"100","author":"Blumensatt","year":"2013","journal-title":"Cardiovasc Res"},{"issue":"15","key":"10.1016\/j.jacasi.2026.06.006_bib55","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.029415","article-title":"Epicardial adipose tissue-derived leptin promotes myocardial injury in metabolic syndrome rats through PKC\/NADPH Oxidase\/ROS pathway","volume":"12","author":"Chen","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib56","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1161\/CIRCRESAHA.115.307856","article-title":"Mutual regulation of epicardial adipose tissue and myocardial redox State by PPAR-\u03b3\/Adiponectin signalling","volume":"118","author":"Antonopoulos","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.jacasi.2026.06.006_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116779","article-title":"Apolipoprotein J protects cardiomyocytes from lipid-mediated inflammation and cytotoxicity induced by the epicardial adipose tissue of diabetic patients","volume":"175","author":"Puig","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib58","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.111.076075","article-title":"Low myocardial protein kinase G activity in heart failure with preserved ejection fraction","volume":"126","author":"van Heerebeek","year":"2012","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib59","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-025-02688-7","article-title":"Exploring the impact of metabolic comorbidities on epicardial adipose tissue in heart failure with preserved ejection fraction","volume":"24","author":"Menghoum","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib60","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1172\/JCI30634","article-title":"IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system","volume":"117","author":"Sanada","year":"2007","journal-title":"J Clin Invest"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib61","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3892\/ijmm.2013.1436","article-title":"Tetramethylpyrazine inhibits angiotensin II-induced cardiomyocyte hypertrophy and tumor necrosis factor-\u03b1 secretion through an NF-\u03baB-dependent mechanism","volume":"32","author":"Yu","year":"2013","journal-title":"Int J Mol Med"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib62","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1253\/circj.CJ-18-0837","article-title":"Circulating activin A is a surrogate for the incidence of diastolic dysfunction and heart failure in patients with preserved ejection fraction","volume":"83","author":"Tsai","year":"2019","journal-title":"Circ J"},{"issue":"13","key":"10.1016\/j.jacasi.2026.06.006_bib63","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/eurheartj\/eht099","article-title":"Human epicardial adipose tissue induces fibrosis of the atrial myocardium through the secretion of adipo-fibrokines","volume":"36","author":"Venteclef","year":"2015","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacasi.2026.06.006_bib64","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/oby.22608","article-title":"Cardioprotective heme Oxygenase-1-PGC1\u03b1 signaling in epicardial fat attenuates cardiovascular risk in humans as in Obese mice","volume":"27","author":"Singh","year":"2019","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib65","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jchf.2024.04.010","article-title":"Screening for unrecognized HFpEF in atrial fibrillation and for unrecognized atrial fibrillation in HFpEF","volume":"12","author":"Reddy","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib66","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1161\/CIRCULATIONAHA.117.030093","article-title":"High prevalence of occult heart failure with preserved ejection fraction among patients with atrial fibrillation and dyspnea","volume":"137","author":"Reddy","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib67","article-title":"The adipose-neural axis is involved in epicardial adipose tissue-related cardiac arrhythmias","volume":"5","author":"Fan","year":"2024","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib68","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1186\/s12864-024-10851-9","article-title":"Characteristics of gene expression in epicardial adipose tissue and subcutaneous adipose tissue in patients at risk for heart failure undergoing coronary artery bypass grafting","volume":"25","author":"Frisk","year":"2024","journal-title":"BMC Genomics"},{"issue":"43","key":"10.1016\/j.jacasi.2026.06.006_bib69","article-title":"Loss of hepatic angiotensinogen attenuates diastolic dysfunction in heart failure with preserved ejection fraction","volume":"12","author":"Heng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jacasi.2026.06.006_bib70","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jare.2024.02.015","article-title":"AdipoRon ameliorates the progression of heart failure with preserved ejection fraction via mitigating lipid accumulation and fibrosis","volume":"68","author":"Tan","year":"2025","journal-title":"J Adv Res"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib71","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1210\/en.2015-2022","article-title":"Retinol-binding protein 4 induces cardiomyocyte hypertrophy by activating TLR4\/MyD88 Pathway","volume":"157","author":"Gao","year":"2016","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib72","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/antiox9121179","article-title":"Downregulation of the Glo1 gene is associated with reduced adiposity and ectopic fat accumulation in spontaneously hypertensive rats","volume":"9","author":"\u0160ilhav\u00fd","year":"2020","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib73","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.bbalip.2019.03.004","article-title":"Involvement of pericardial adipose tissue in cardiac fibrosis of dietary-induced obese minipigs- role of mitochondrial function","volume":"1864","author":"Li","year":"2019","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib74","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/CIRCHEARTFAILURE.114.001279","article-title":"Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction","volume":"7","author":"Tanaka","year":"2014","journal-title":"Circ Heart Fail"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/en.2009-0806","article-title":"Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure","volume":"151","author":"Sam","year":"2010","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib76","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1097\/HJH.0000000000000149","article-title":"Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity","volume":"32","author":"Mart\u00ednez-Mart\u00ednez","year":"2014","journal-title":"J Hypertens"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib77","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006414","article-title":"Obese-inflammatory phenotypes in heart failure with preserved ejection fraction","volume":"13","author":"Sabbah","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib78","article-title":"White adipose tissue in obesity-associated HFpEF: insights from mice and humans","volume":"10","author":"Valero-Mu\u00f1oz","year":"2025","journal-title":"JACC Basic Transl Sci"},{"issue":"11","key":"10.1016\/j.jacasi.2026.06.006_bib79","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/CIRCRESAHA.125.326251","article-title":"Inhibition of adipose tissue lipolysis treats obesity-related HFpEF","volume":"136","author":"Stockner","year":"2025","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.jacasi.2026.06.006_bib80","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib81","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1161\/CIRCULATIONAHA.117.031358","article-title":"Visceral adipose tissue drives cardiac aging through modulation of fibroblast senescence by osteopontin production","volume":"138","author":"Sawaki","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib82","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3390\/antiox10050769","article-title":"Galangin resolves cardiometabolic disorders through modulation of AdipoR1, COX-2, and NF-\u03baB expression in rats fed a high-fat diet","volume":"10","author":"Prasatthong","year":"2021","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.jacasi.2026.06.006_bib83","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ijcard.2016.11.194","article-title":"HFpEF and HFrEF exhibit different phenotypes as assessed by leptin and adiponectin","volume":"228","author":"Fax\u00e9n","year":"2017","journal-title":"Int J Cardiol"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib84","doi-asserted-by":"crossref","first-page":"984","DOI":"10.2337\/diab.45.7.984","article-title":"Adipose tissue leptin production and plasma leptin kinetics in humans","volume":"45","author":"Klein","year":"1996","journal-title":"Diabetes"},{"issue":"22","key":"10.1016\/j.jacasi.2026.06.006_bib85","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1161\/CIRCULATIONAHA.115.018226","article-title":"Adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis","volume":"132","author":"Huby","year":"2015","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib86","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1161\/HYPERTENSIONAHA.115.06642","article-title":"Leptin induces hypertension and endothelial dysfunction via aldosterone-dependent mechanisms in obese female mice","volume":"67","author":"Huby","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.jacasi.2026.06.006_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116558","article-title":"Effects and mechanism of Compound Qidan Formula on rats with HFpEF induced by hypertension and diabetes mellitus based on Ang \u2161\/TGF-\u03b21\/Smads signaling pathway","volume":"313","author":"Yuan","year":"2023","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"10.1016\/j.jacasi.2026.06.006_bib88","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib89","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12933-025-02720-w","article-title":"Epicardial adipose tissue and heterogeneity parameters combined with inflammatory cells to predict the value of heart failure with preserved ejection fraction patients post myocardial infarction","volume":"24","author":"Song","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"24","key":"10.1016\/j.jacasi.2026.06.006_bib90","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.124.036789","article-title":"Prognostic value of epicardial adipose tissue in heart failure with mid-range and preserved ejection fraction: a multicenter study","volume":"13","author":"Wang","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib91","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/ejhf.2513","article-title":"Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction","volume":"24","author":"Jin","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib92","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1002\/ejhf.2709","article-title":"Association of epicardial adipose tissue with proteomics, coronary flow reserve, cardiac structure and function, and quality of life in heart failure with preserved ejection fraction: insights from the PROMIS-HFpEF study","volume":"24","author":"Venkateshvaran","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacasi.2026.06.006_bib93","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/oby.2008.6","article-title":"Threshold values of high-risk echocardiographic epicardial fat thickness","volume":"16","author":"Iacobellis","year":"2008","journal-title":"Obesity (Silver Spring)"},{"issue":"22","key":"10.1016\/j.jacasi.2026.06.006_bib94","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","article-title":"Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF","volume":"70","author":"Tsujimoto","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib95","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1017\/S0007114519003301","article-title":"A simple cut-off for waist-to-height ratio (0\u00b75) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England","volume":"123","author":"Gibson","year":"2020","journal-title":"Br J Nutr"},{"issue":"3-4","key":"10.1016\/j.jacasi.2026.06.006_bib96","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cob.12021","article-title":"A correlation between the weight of visceral adipose tissue and selected anthropometric indices: an autopsy study","volume":"3","author":"Edston","year":"2013","journal-title":"Clin Obes"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib97","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s12872-021-02080-9","article-title":"Waist to height ratio is associated with an increased risk of mortality in Chinese patients with heart failure with preserved ejection fraction","volume":"21","author":"Chen","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib98","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jchf.2013.11.007","article-title":"Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis","volume":"2","author":"Savarese","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"22","key":"10.1016\/j.jacasi.2026.06.006_bib99","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic implications of changes in N-Terminal Pro-B-Type natriuretic peptide in patients with heart failure","volume":"68","author":"Zile","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.jacasi.2026.06.006_bib100","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/CIRCULATIONAHA.125.073788","article-title":"Natriuretic peptides for the diagnosis of heart failure with preserved ejection fraction","volume":"151","author":"Omland","year":"2025","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jcmg.2020.07.022","article-title":"Body composition, natriuretic peptides, and adverse outcomes in heart failure with preserved and reduced ejection fraction","volume":"14","author":"Selvaraj","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib102","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10741-021-10160-3","article-title":"A systematic review exploring the significance of measuring epicardial fat thickness in correlation to B-type natriuretic peptide levels as prognostic and diagnostic markers in patients with or at risk of heart failure","volume":"27","author":"Nyawo","year":"2022","journal-title":"Heart Fail Rev"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib103","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijcard.2014.08.007","article-title":"Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure","volume":"176","author":"Madamanchi","year":"2014","journal-title":"Int J Cardiol"},{"issue":"15","key":"10.1016\/j.jacasi.2026.06.006_bib104","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1161\/CIRCULATIONAHA.117.032474","article-title":"Leptin-Aldosterone-Neprilysin axis: identification of its distinctive role in the pathogenesis of the three phenotypes of heart failure in people with obesity","volume":"137","author":"Packer","year":"2018","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100941","article-title":"Diet-dependent natriuretic peptide receptor C expression in adipose tissue is mediated by PPAR\u03b3 via long-range distal enhancers","volume":"297","author":"Shi","year":"2021","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib106","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1038\/ijo.2010.227","article-title":"Neprilysin, obesity and the metabolic syndrome","volume":"35","author":"Standeven","year":"2011","journal-title":"Int J Obes (Lond)"},{"issue":"10431","key":"10.1016\/j.jacasi.2026.06.006_bib107","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib108","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jacc.2025.06.036","article-title":"Evidentiary landscape of heart failure therapies, regulatory decisions, and translation into guidelines","volume":"86","author":"Kaul","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10437","key":"10.1016\/j.jacasi.2026.06.006_bib109","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-Neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib111","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","article-title":"Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone","volume":"8","author":"Cohen","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib112","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jchf.2023.03.011","article-title":"How to manage heart failure with preserved ejection fraction: practical guidance for clinicians","volume":"11","author":"Desai","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"8 Pt 1","key":"10.1016\/j.jacasi.2026.06.006_bib113","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib114","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1161\/CIRCRESAHA.122.320257","article-title":"Heart failure with preserved ejection fraction: heterogeneous syndrome, diverse preclinical models","volume":"130","author":"Roh","year":"2022","journal-title":"Circ Res"},{"issue":"32","key":"10.1016\/j.jacasi.2026.06.006_bib115","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1093\/eurheartj\/ehab431","article-title":"PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction","volume":"42","author":"Da Dalt","year":"2021","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib116","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/ejhf.3046","article-title":"Exercise-based cardiac rehabilitation for adults with heart failure - 2023 cochrane systematic review and meta-analysis","volume":"25","author":"Molloy","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12872-025-04649-0","article-title":"Impact of exercise training on exercise tolerance, cardiac function and quality of life in individuals with heart failure and preserved ejection fraction: a systematic review and meta-analysis","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib118","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41591-024-03342-7","article-title":"Combined endurance and resistance exercise training in heart failure with preserved ejection fraction: a randomized controlled trial","volume":"31","author":"Edelmann","year":"2025","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jacasi.2026.06.006_bib119","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.jacc.2011.06.054","article-title":"Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (exercise training in diastolic heart failure) pilot study","volume":"58","author":"Edelmann","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.jacasi.2026.06.006_bib120","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjsports-2022-106304","article-title":"Dose-response effects of exercise and caloric restriction on visceral adiposity in overweight and obese adults: a systematic review and meta-analysis of randomised controlled trials","volume":"57","author":"Recchia","year":"2023","journal-title":"Br J Sports Med"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/jama.2015.17346","article-title":"Effect of caloric restriction or aerobic exercise training on peak oxygen consumption and quality of life in Obese older patients with heart failure with preserved ejection fraction: a randomized clinical trial","volume":"315","author":"Kitzman","year":"2016","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.jacasi.2026.06.006_bib122","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.jacasi.2026.06.006_bib123","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2024.08.028","article-title":"Inflammation in obesity-related HFpEF: the STEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib124","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacasi.2026.06.006_bib125","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"35","key":"10.1016\/j.jacasi.2026.06.006_bib126","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib127","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.jacasi.2026.06.006_bib128","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.jacc.2025.06.058","article-title":"Influence of type 2 diabetes on the effects of tirzepatide in patients with heart failure and a preserved ejection fraction with obesity: a prespecified stratification-based analysis","volume":"86","author":"Packer","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacasi.2026.06.006_bib129","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1016\/j.jchf.2024.07.006","article-title":"GLP-1 receptor agonists among patients with overweight or obesity, diabetes, and HFpEF on SGLT2 inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"12","key":"10.1016\/j.jacasi.2026.06.006_bib130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacasi.2026.06.006_bib131","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib132","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12933-025-02756-y","article-title":"Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial","volume":"24","author":"Ovchinnikov","year":"2025","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"10.1016\/j.jacasi.2026.06.006_bib133","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.010080","article-title":"Efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction according to age: the DELIVER trial","volume":"15","author":"Peikert","year":"2022","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacasi.2026.06.006_bib134","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/cvr\/cvx186","article-title":"Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability","volume":"114","author":"D\u00edaz-Rodr\u00edguez","year":"2018","journal-title":"Cardiovasc Res"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib135","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12933-023-02091-0","article-title":"Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes","volume":"22","author":"Cinti","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.jacasi.2026.06.006_bib136","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011107","article-title":"Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain","volume":"17","author":"Schauer","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"8","key":"10.1016\/j.jacasi.2026.06.006_bib137","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1038\/s41401-024-01265-0","article-title":"Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway","volume":"45","author":"Ni","year":"2024","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"10.1016\/j.jacasi.2026.06.006_bib138","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1001\/jamacardio.2023.1090","article-title":"Safety and efficacy of empagliflozin and diuretic use in patients with heart failure and preserved ejection fraction: a post hoc analysis of the EMPEROR-preserved trial","volume":"8","author":"Butler","year":"2023","journal-title":"JAMA Cardiol"},{"issue":"1","key":"10.1016\/j.jacasi.2026.06.006_bib139","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-025-04037-3","article-title":"Lifetime benefits of comprehensive medical therapy in heart failure with mildly reduced or preserved ejection fraction","volume":"32","author":"Vaduganathan","year":"2026","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jacasi.2026.06.006_bib140","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/eurjpc\/zwac290","article-title":"Association of genetically predicted lipid traits and lipid-modifying targets with heart failure","volume":"30","author":"Xiao","year":"2023","journal-title":"Eur J Prev Cardiol"},{"issue":"16","key":"10.1016\/j.jacasi.2026.06.006_bib141","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"issue":"10481","key":"10.1016\/j.jacasi.2026.06.006_bib142","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the global burden of disease study 2021","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.06.006_bib143","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1196\/annals.1341.019","article-title":"Metabolic energetics and genetics in the heart","volume":"1047","author":"Taegtmeyer","year":"2005","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"10.1016\/j.jacasi.2026.06.006_bib144","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/ejhf.1617","article-title":"Myocardial adipose deposition and the development of heart failure with preserved ejection fraction","volume":"22","author":"Wu","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.jacasi.2026.06.006_bib145","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1093\/eurheartj\/ehaa823","article-title":"Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction","volume":"42","author":"Sorimachi","year":"2021","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacasi.2026.06.006_bib146","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: step-hfpef trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726004321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726004321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T20:30:39Z","timestamp":1784838639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726004321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":146,"alternative-id":["S2772374726004321"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.06.006","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiac-Adipose Axis in Heart Failure With Preserved Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}